Comparative Pharmacology
Head-to-head clinical analysis: CIPROFLOXACIN EXTENDED RELEASE versus FLOXIN IN DEXTROSE 5.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CIPROFLOXACIN EXTENDED RELEASE versus FLOXIN IN DEXTROSE 5.
CIPROFLOXACIN EXTENDED RELEASE vs FLOXIN IN DEXTROSE 5%
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Inhibits bacterial DNA gyrase (topoisomerase II) and topoisomerase IV, preventing DNA replication, transcription, repair, and recombination.
Inhibits bacterial DNA gyrase (topoisomerase II) and topoisomerase IV, preventing DNA replication and transcription.
500-1000 mg orally once daily for 7-14 days; extended-release tablet must be taken whole with a meal.
400 mg intravenously every 12 hours.
None Documented
None Documented
Terminal elimination half-life approximately 11 hours, ranging from 10-14 hours in patients with normal renal function. Prolonged in renal impairment; requires dose adjustment.
Terminal elimination half-life: 6-8 hours (prolonged in renal impairment, up to 20-30 hours in severe impairment).
Primarily renal excretion (50-70% unchanged drug via glomerular filtration and tubular secretion); 15-25% metabolized; 20-35% fecal elimination via biliary secretion and intestinal epithelium.
Primarily renal (approximately 70-90% unchanged drug), with 5-10% biliary/fecal elimination.
Category C
Category C
Fluoroquinolone Antibiotic
Fluoroquinolone Antibiotic